Erlotinib (Erlocip) Tablet – Treatment for Lung And Pancreatic Cancer
Erlocip 150 Tablet is a cancer medication that is used to treat non-small cell lung cancer and pancreatic cancer.
Non-small cell lung cancer is one of the most common types of lung cancer, affecting both smokers and non-smokers. Erlocip 150 Tablet is used to treat non-small cell lung cancer and can be used alone or in conjunction with other medications. It is a strong and very poisonous medication, and you should see your doctor about the dangers and advantages. To be hydrated, you should avoid consuming alcohol throughout this therapy and drink lots of water.
Because they create the body’s own insulin, the pancreas is critical for digestion as well as blood sugar metabolism. This drug will assist in the treatment of pancreatic cancer by reducing symptoms such as appetite loss and unexplained weight loss. Erlocip 150 Tablet inhibits the activity of substances that promote pancreatic cancer development and spread. It will assist you in living a longer and healthier life.
Erlocip 150 Tablet should be taken on an empty stomach, or one hour before or two hours after a meal. You should continue to take it for as long as your doctor recommends. The length of therapy is determined by your requirements and reaction to treatment. You should take it precisely as prescribed by your doctor. If used wrongly or in excess, it might have serious side effects. It may take many weeks or months for you to notice or feel the advantages, but do not stop taking it until your doctor instructs you to do so.
USES OF ERLOTINIB (ERLOCIP) TABLET
- In Non-small cell lung cancer
- In Pancreatic cancer
WORK OF ERLOTINIB (ERLOCIP) TABLET
Erlocip 150 Tablet is a cancer-fighting medicine. On the surfaces of lung cancer cells, epidermal growth factor receptors (EGFR) are expressed, which modulates their proliferation. This medication acts by binding the chemical messenger EGFR and thereby inhibiting the cancer signaling pathways controlled by EGFR. This is how it prevents cancer cells from growing further.
DIRECTIONS FOR USE:
Take this medication exactly as directed by your doctor, for the duration and at the dose advised. Take everything at once. It must not be eaten, crushed, or damaged in any way. Erlocip 150 Tablet should be taken first thing in the morning on an empty stomach.
SIDE EFFECTS OF ERLOTINIB (ERLOCIP) TABLET
- Abdominal pain
- Bone pain
- Muscle pain
- Stomatitis (Inflammation of the mouth)
- Weight loss
WARNINGS OF PRECAUTIONS
It is unknown whether Erlocip 150 Tablet impairs driving abilities. If you have any symptoms that impair your ability to focus or respond, do not drive.
In people with renal illness, Erlocip 150 Tablet is safe to use. There is no need to alter the dose of Erlocip 150 Tablet.
This medication should not be used in people who have severe renal disease.
In individuals with liver problems, Erlocip 150 Tablet should be taken with care. Erlocip 150 Tablet dosage may need to be adjusted. Please visit your physician.
There is little information on the usage of Erlocip 150 Tablet in these individuals. In individuals with mild to severe liver disease, no dosage change is indicated.
Erlocip 150 Tablet should not be used during pregnancy since there is clear evidence of danger to the developing infant. However, if the advantages outweigh the hazards, the doctor may seldom prescribe it in life-threatening conditions. Please visit your physician.
Erlocip 150 Tablet is most likely hazardous to take during nursing. According to limited human research, the medication may transfer into breastmilk and damage the infant.
Fedelty Health Care is an Erlotinib third-party manufacturer, bulk pharma exporter, and pharmaceutical contract manufacturer operating businesses in Venezuela, Saudi Arabia, Cambodia, Oman, Brazil, Lebanon, Chile, Peru, Cuba, and Fiji. Other services they provide are hospital supply, government supply, named patient supply, cold chain supply, and drop shipping.